124 results on '"Fenaux, P."'
Search Results
2. Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial.
- Author
-
Platzbecker, U, Sekeres, M A, Kantarjian, H, Giagounidis, A, Mufti, G J, Jia, C, Yang, A S, and Fenaux, P
- Subjects
MYELODYSPLASTIC syndromes ,HEALTH outcome assessment ,PLATELET count ,BLOOD platelet transfusion ,AZACITIDINE ,DECITABINE ,PATIENTS - Abstract
The article explores the connection of platelet response criteria and patient outcomes in myelodysplastic syndromes trial with romiplostim. An improvement in platelet count is noted following the use of romiplostim as monotherapy and in combination with azacitidine, decitabine or lenalidomide. The relation of romiplostim treatment with platelet response by all the criteria studied is noted. The likelihood of the patients to require platelet transfusions is also shown in all the criteria.
- Published
- 2014
- Full Text
- View/download PDF
3. Epigenetics of myelodysplastic syndromes.
- Author
-
Itzykson, R and Fenaux, P
- Abstract
Myelodysplastic syndromes (MDS) are clonal diseases of the elderly characterized by chronic cytopenias, dysplasia and a variable risk of progression to acute myeloid leukemia (AML). Aberrant methylation of tumor-suppressor gene promoters has been established for many years and recently tracked to the most immature cells of MDS, suggesting that these alterations are drivers of MDS pathogenesis. In recent years, recurrent somatic mutations in genes encoding proteins involved in DNA methylation and demethylation and in covalent histone modifications have been reported in myeloid malignancies, including MDS. Whole-genome epigenetic profiles of MDS are also emerging. In parallel with these advances in the molecular pathogenesis of MDS, clinical trials have established hypomethylating agents (HMAs) as the mainstay of therapy in the advanced forms of the disease. In this review, we summarize the current understanding of the molecular machinery involved in epigenetic regulation, discuss how epigenetic alterations arise in MDS and contribute to its pathogenesis and then discuss the mode of action of HMAs in MDS. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
4. A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q).
- Author
-
Sardnal, V, Rouquette, A, Kaltenbach, S, Bally, C, Chesnais, V, Leschi, C, Ades, L, Santini, V, Park, S, Toma, A, Fenaux, P, Dreyfus, F, Fontenay, M, and Kosmider, O
- Subjects
MYELODYSPLASTIC syndromes ,BIOMARKERS ,UBIQUITIN ligases ,GENE expression ,GENETIC polymorphisms - Abstract
The article presents a study which shows the role of A/G polymorphism in the E3 ubiquitin ligase protein Cereblon (CRBN) gene as biomarker of response to treatment with lenalidomide. It notes that 66 patients with myelodysplastic syndromes (MDS) received lenalidomide for 21 days and the role of CRBN gene in the response to lenalidomide was investigated in the study. Furthermore, the study determined that CRBN expression level does not seem to be involved in lenalidomide in low/int-1 MDS.
- Published
- 2013
- Full Text
- View/download PDF
5. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents.
- Author
-
Kelaidi, C, Park, S, Sapena, R, Beyne-Rauzy, O, Coiteux, V, Vey, N, Stamatoullas, A, Choufi, B, Delaunay, J, Gourin, M-P, Cheze, S, Ravoet, C, Ferrant, A, Escoffre-Barbe, M, Aljassem, L, Raffoux, E, Itzykson, R, Adès, L, Dreyfus, F, and Fenaux, P
- Subjects
ACUTE myeloid leukemia ,ANEMIA ,MYELODYSPLASTIC syndromes ,BONE marrow diseases ,CHROMOSOME abnormalities -- Risk factors ,DISEASE complications ,DISEASE risk factors - Abstract
A large proportion of lower-risk myelodysplastic syndromes (MDS) respond to erythropoiesis-stimulating agents (ESA), but most responses are transient. We updated a previously reported cohort of lower-risk MDS patients treated with ESA and analyzed outcomes after ESA failure. In 120 patients with primary resistance and 66 patients with relapse after an initial response to ESA, the 5-year cumulative incidence of acute myeloid leukemia (AML) after failure was 18.9% and 11.6%, respectively (P=0.20). Median overall survival (OS) after failure was 40.1 and 44.9 months (P=0.35), respectively. We further categorized patients as 'early failures' (including resistance and relapse after <6 months of response), or 'later failures' (that is, relapse after 6 months). The 5-year cumulative incidence of AML and median OS after failure in early and later failure were 21.6% and 9% (P=0.02) and 36.7 and 54.3 months (P=0.02), respectively. Early failure to ESA and a baseline diagnosis of refractory anemia with excess blasts (RAEB)-1 were independent prognostic factors for AML progression and, along with trisomy 8, for shorter OS. Median OS from treatment onset was 40, 90.7 and 65.8 months in early failure, later failure and no relapse, respectively (P=0.001). Lower-risk MDS with early failure to ESA have a relatively unfavorable outcome, and should be offered alternative treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
6. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
- Author
-
Kuendgen, A, Lauseker, M, List, A F, Fenaux, P, Giagounidis, A A, Brandenburg, N A, Backstrom, J, Glasmacher, A, Hasford, J, and Germing, U
- Subjects
ACUTE myeloid leukemia ,DISEASE progression ,RED blood cell transfusion ,MYELODYSPLASTIC syndromes ,COMPARATIVE studies ,PATIENTS - Abstract
Data comparing long-term outcomes in lenalidomide-treated and untreated patients with myelodysplastic syndromes (MDS) with del(5q) are limited. We evaluated clinical outcomes of 295 lenalidomide-treated patients from two clinical trials (MDS-003 and MDS-004) and 125 untreated red blood cell (RBC) transfusion-dependent patients with del(5q) Low- or Intermediate-1 (Int-1)-risk MDS from a large multicenter registry. Risk factors for acute myeloid leukemia (AML) progression and mortality were assessed using Cox proportional hazards models with left truncation to adjust for study entry differences between cohorts. Baseline characteristics were well balanced across cohorts, except for a higher RBC transfusion burden in lenalidomide-treated patients (median, 6 vs 2 units/8 weeks). Median follow-up was 4.3 years from first dose for lenalidomide-treated patients and 4.6 years from diagnosis for untreated patients. Two-year cumulative AML progression incidences were 6.9% (95% confidence interval (CI): 3.3-13.9) and 12.1% (95% CI: 7.0-20.3) and 2-year overall survival (OS) probabilities were 89.9% (95% CI: 84.1-96.0) and 74.4% (95% CI: 66.1-83.7), respectively. AML progression risk was similar in both cohorts (hazard ratio (HR) 0.969, P=0.930); however, lenalidomide treatment was associated with significant improvement in survival (HR 0.597, P=0.012), after adjusting for all other covariates. In conclusion, lenalidomide treatment does not increase AML progression risk, but instead confers a possible survival benefit in RBC transfusion-dependent patients with del(5q) Low- or Int-1-risk MDS. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
7. Successful xenografts of AML3 samples in immunodeficient NOD/shi-SCID IL2Rγ−/− mice.
- Author
-
Patel, S, Zhang, Y, Cassinat, B, Zassadowski, F, Ferré, N, Cuccuini, W, Cayuela, J M, Fenaux, P, Bonnet, D, Chomienne, C, and Louache, F
- Subjects
LETTERS to the editor ,ACUTE myeloid leukemia treatment ,LABORATORY mice - Abstract
A letter to the editor is presented which discusses the success of the xenografts of acute myeloid leukemia 3 (AML3) samples in immunodeficient mice.
- Published
- 2012
- Full Text
- View/download PDF
8. Successful xenografts of AML3 samples in immunodeficient NOD/shi-SCID IL2R[gamma](-/-) mice.
- Author
-
Patel S, Zhang Y, Cassinat B, Zassadowski F, Ferré N, Cuccuini W, Cayuela JM, Fenaux P, Bonnet D, Chomienne C, and Louache F
- Published
- 2012
- Full Text
- View/download PDF
9. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
- Author
-
Renneville, A, Boissel, N, Nibourel, O, Berthon, C, Helevaut, N, Gardin, C, Cayuela, J-M, Hayette, S, Reman, O, Contentin, N, Bordessoule, D, Pautas, C, Botton, S de, Revel, T de, Terre, C, Fenaux, P, Thomas, X, Castaigne, S, Dombret, H, and Preudhomme, C
- Subjects
DNA methyltransferases ,ACUTE myeloid leukemia ,NUCLEOPHOSMIN ,ISOCITRATE dehydrogenase ,MULTIVARIATE analysis ,KARYOTYPES ,GENETICS - Abstract
Recently, DNA methyltransferase 3A (DNMT3A) mutations have been identified in acute myeloid leukemia (AML), the highest frequency being found within cytogenetically normal (CN) AML. In this study, diagnostic samples from 123 adults younger than 60 years with primary CN-AML homogeneously treated in the Acute Leukemia French Association-9801 and -9802 trials were screened for mutations in DNMT3A-conserved domains by direct sequencing. Patients were also assessed for the presence of FLT3 (fms-like tyrosine kinase receptor-3), NPM1 (nucleophosmin), CEBPA, WT1 (Wilms tumor 1), IDH1 (isocitrate dehydrogenase 1) and IDH2 mutations. Thirty-eight mutations were detected in 36 patients (29%): 36 nucleotide substitutions, mostly affecting amino-acid residue R882 and two frameshift deletions. DNMT3A mutations were significantly associated with the French-American-British subtypes M4/M5 and the presence of NPM1 mutations. In the whole cohort, DNMT3A mutated patients had a shorter event-free survival (5-year EFS: 13% vs 32%, P=0.02) and overall survival (5-year OS: 23% vs 45%, P=0.02) compared with DNMT3A wild-type patients. In multivariate analysis including age, white blood cell count, NPM1/FLT3-internal tandem duplication/CEBPA risk group and DNMT3A mutational status, the presence of a DNMT3A mutation remained an independent adverse prognostic factor for EFS and OS, suggesting that testing for DNMT3A mutations could help further improve risk stratification in CN-AML. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
10. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study.
- Author
-
Germing, U, Lauseker, M, Hildebrandt, B, Symeonidis, A, Cermak, J, Fenaux, P, Kelaidi, C, Pfeilstöcker, M, Nösslinger, T, Sekeres, M, Maciejewski, J, Haase, D, Schanz, J, Seymour, J, Kenealy, M, Weide, R, Lübbert, M, Platzbecker, U, Valent, P, and Götze, K
- Subjects
MYELODYSPLASTIC syndromes ,ACUTE myeloid leukemia ,PROGNOSIS ,DISEASE progression ,BLOOD transfusion - Abstract
Myelodysplastic syndromes (MDS) with del(5q) are considered to have a benign course of the disease. In order to address the issue of the propensity of those patients to progress to acute myeloid leukemia (AML), data on 381 untreated patients with MDS and del(5q) characterized by low or intermediate I International Prognostic Scoring System (IPSS) risk score were collected from nine centers and registries. Median survival of the entire group was 74 months. Transfusion-dependent patients had a median survival of 44 months vs 97 months for transfusion-independent patients (P<0.0001). Transfusion need at diagnosis was the most important patient characteristic for survival. Of the 381 patients, 48 (12.6%) progressed to AML. The cumulative progression rate calculated using the Kaplan-Meier method was 4.9% at 2 years and 17.6% at 5 years. Factors associated with the risk of AML transformation were high-risk World Health Organization adapted Prognostic Scoring System (WPSS) score, marrow blast count >5% and red-cell transfusion dependency at diagnosis. In conclusion, patients with MDS and del(5q) are facing a considerable risk of AML transformation. More detailed cytogenetic and molecular studies may help to identify the patients at risk of progression. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
11. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
- Author
-
Itzykson, R., Kosmider, O., Cluzeau, T., Mansat-De Mas, V., Beyne-Rauzy, F., Quesnel, B., Vey, N., Gelsi-Boyer, V., Raynaud, S., Preudhomme, C., Adès, L., Fenaux, P., Fontenay, M., Beyne-Rauzy, O., Dreyfus, F., Adès, L, and Groupe Francophone des Myelodysplasies (GFM)
- Subjects
AZACITIDINE ,MYELODYSPLASTIC syndromes ,ACUTE myeloid leukemia ,CHROMOSOMAL translocation ,HUMAN cytogenetics - Abstract
The impact of ten-eleven-translocation 2 (TET2) mutations on response to azacitidine (AZA) in MDS has not been reported. We sequenced the TET2 gene in 86 MDS and acute myeloid leukemia (AML) with 20-30% blasts treated by AZA, that is disease categories wherein this drug is approved by Food and Drug Administration (FDA). Thirteen patients (15%) carried TET2 mutations. Patients with mutated and wild-type (WT) TET2 had mostly comparable pretreatment characteristics, except for lower hemoglobin, better cytogenetic risk and longer MDS duration before AZA in TET2 mutated patients (P=0.03, P=0.047 and P=0.048, respectively). The response rate (including hematological improvement) was 82% in MUT versus 45% in WT patients (P=0.007). Mutated TET2 (P=0.04) and favorable cytogenetic risk (intermediate risk: P=0.04, poor risk: P=0.048 compared with good risk) independently predicted a higher response rate. Response duration and overall survival were, however, comparable in the MUT and WT groups. In higher risk MDS and AML with low blast count, TET2 status may be a genetic predictor of response to AZA, independently of karyotype. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
12. PML–RARα ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL.
- Author
-
Schachter-Tokarz, E., Kelaidi, C., Cassinat, B., Chomienne, C., Gardin, C., Raffoux, E., Dombret, H., Fenaux, P., and Gallagher, R.
- Subjects
LETTERS to the editor ,GENES - Abstract
A letter to the editor in response to the article "PML-RARα ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APLWilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies," published in a previous issue is presented.
- Published
- 2010
- Full Text
- View/download PDF
13. Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms.
- Author
-
Kiladjian, J-J., Chomienne, C., and Fenaux, P.
- Subjects
INTERFERONS ,CYTOKINES ,MYELOPROLIFERATIVE neoplasms ,POLYCYTHEMIA ,HEMATOLOGICAL oncology ,TUMORS ,HEMATOPOIESIS ,POISONS ,PREGNANCY - Abstract
Interferon (IFN) was the first cytokine discovered 50 years ago, with a wide range of biological properties, including immunomodulatory, proapoptotic and antiangiogenic activities, that rapidly raised interest in its therapeutic use in malignancies. IFN-receptor characterization was also pivotal in the discovery of the JAK/STAT signaling pathway. Among the large IFN family, mainly one of the type I IFN, IFN-α2, is used in therapy. Many clinical trials have shown remarkable efficacy of IFN-α in bcr-abl-negative myeloproliferative neoplasms (MPNs), especially polycythemia vera (PV), and essential thrombocythemia (ET). IFN-α induces about 80% of hematological responses in those diseases and is able to reduce splenomegaly, as well as relieve pruritus and other constitutional symptoms. Yet its use was limited by toxicity, leading to early treatment discontinuation in about 20% of the patients. However, its lack of leukemogenic potential and its possible use during pregnancy have already made IFN-α the drug of choice for younger MPN patients. In addition, several studies have shown a probably selective effect of IFN-α on PV and ET clones, as shown by cytogenetic remissions, reversions to polyclonal hematopoiesis, and more recently by induction of JAK2V617F complete molecular remissions in PV which may widen the indications of IFN-α in JAK2-mutated MPN. [ABSTRACT FROM AUTHOR]
- Published
- 2008
14. Cooperating gene mutations in acute myeloid leukemia: a review of the literature.
- Author
-
Renneville, A., Roumier, C., Biggio, V., Nibourel, O., Boissel, N., Fenaux, P., and Preudhomme, C.
- Subjects
ACUTE myeloid leukemia ,GENES ,LEUKEMIA etiology ,CYTOGENETICS ,CELL cycle ,APOPTOSIS - Abstract
Acute myeloid leukemia (AML) is a heterogeneous group of neoplastic disorders with great variability in clinical course and response to therapy, as well as in the genetic and molecular basis of the pathology. Major advances in the understanding of leukemogenesis have been made by the characterization and the study of acquired cytogenetic abnormalities, particularly reciprocal translocations observed in AML. Besides these major cytogenetic abnormalities, gene mutations also constitute key events in AML pathogenesis. In this review, we describe the contribution of known gene mutations to the understanding of AML pathogenesis and their clinical significance. To gain more insight in this understanding, we clustered these alterations in three groups: (1) mutations affecting genes that contribute to cell proliferation (FLT3, c-KIT, RAS, protein tyrosine standard phosphatase nonreceptor 11); (2) mutations affecting genes involved in myeloid differentiation (AML1 and CEBPA) and (3) mutations affecting genes implicated in cell cycle regulation or apoptosis (P53, NPM1). This nonexhaustive review aims to show how gene mutations interact with each other, how they contribute to refine prognosis and how they can be useful for risk-adapted therapeutic management of AML patients.Leukemia (2008) 22, 915–931; doi:10.1038/leu.2008.19; published online 21 February 2008 [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
15. Meeting report: myelodysplastic syndromes at ASH 2007.
- Author
-
Itzykson, R., Gardin, C., and Fenaux, P.
- Subjects
MEETINGS ,MYELODYSPLASTIC syndromes ,BONE marrow diseases ,MOLECULAR genetics ,MOLECULAR biology - Abstract
Myelodysplastic syndromes (MDS) remain challenging to both clinicians and biologists. This year's edition of the Annual Meeting of the American Society of Hematology has provided several breakthroughs in the biology and therapeutics of MDS, such as uncovering of the molecular genetics of the 5q− syndrome and clear evidence of a survival advantage with a hypomethylating agent in high-risk MDS. We summarize those advances and delineate some perspectives for these diseases.Leukemia (2008) 22, 893–897; doi:10.1038/leu.2008.45; published online 6 March 2008 [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
16. History of infections and vaccinations and risk of lymphoid neoplasms: does influenza immunization reduce the risk?
- Author
-
Monnereau, A., Orsi, L., Troussard, X., Berthou, C., Fenaux, P., Marit, G., Soubeyran, P., Huguet, F., Milpied, N., Leporrier, M., Hemon, D., and Clavel, J.
- Subjects
LETTERS to the editor ,IMMUNIZATION - Abstract
A letter to the editor is presented which offers a study on the effectiveness of influenza immunization in lessening the risk of lymphoid neoplasms.
- Published
- 2007
- Full Text
- View/download PDF
17. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial.
- Author
-
Tavernier, E., Boiron, J.-M., Huguet, F., Bradstock, K., Vey, N., Kovacsovics, T., Delannoy, A., Fegueux, N., Fenaux, P., Stamatoullas, A., Tournilhac, O., Buzyn, A., Reman, O., Charrin, C., Boucheix, C., Gabert, J., Lhéritier, V., Vernant, J.-P., Dombret, H., and Thomas, X.
- Subjects
LYMPHOBLASTIC leukemia ,DRUG therapy ,AUTOTRANSPLANTATION ,TRANSPLANTATION of organs, tissues, etc. ,CANCER relapse ,STEM cell transplantation - Abstract
Fifty-four percent of adults with acute lymphoblastic leukemia (ALL) who entered the LALA-94 trial experienced a first relapse. We examined the outcome of these 421 adult patients. One hundred and eighty-seven patients (44%) achieved a second complete remission (CR). The median disease-free survival (DFS) was 5.2 months with a 5-year DFS at 12%. Factors predicting a better outcome after relapse were any transplant performed in second CR (P<0.0001), a first CR duration >1 year (P=0.04) and platelet level >100 × 10
9 /l at relapse (P=0.04). Risk groups defined at diagnosis and treatment received in first CR did not influence the outcome after relapse. The best results were obtained in a subset of patients who were eligible for allogeneic stem cell transplantation (SCT). Geno-identical allogeneic SCT was performed in 55 patients, and 3 patients received donor lymphocyte infusions. Forty-four transplantations were performed from an unrelated donor (of which four were cord blood). We conclude that most adult patients with recurring ALL could not be rescued using current available therapies, although allogeneic SCT remains the best therapeutic option.Leukemia (2007) 21, 1907–1914; doi:10.1038/sj.leu.2404824; published online 5 July 2007 [ABSTRACT FROM AUTHOR]- Published
- 2007
- Full Text
- View/download PDF
18. Effect of priming with granulocyte–macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.
- Author
-
Thomas, X., Raffoux, E., Botton, S. de, Pautas, C., Arnaud, P., de Revel, T., Reman, O., Terré, C., Corront, B., Gardin, C., Le, Q.-H., Quesnel, B., Cordonnier, C., Bourhis, J.-H., Elhamri, M., Fenaux, P., Preudhomme, C., Michallet, M., Castaigne, S., and Dombret, H.
- Subjects
ACUTE myeloid leukemia treatment ,GRANULOCYTE-macrophage colony-stimulating factor ,ACUTE leukemia ,HEMATOPOIETIC growth factors ,CANCER cells - Abstract
In a multicenter trial, 259 young adults (15–49 years) with newly diagnosed acute myeloid leukemia (AML) were first randomized to receive a timed-sequential induction regimen given either alone (135 patients) or concomitantly with granulocyte–macrophage colony-stimulating factor (GM-CSF) (124 patients). Patients reaching complete remission (CR) were then randomized to compare a timed-sequential consolidation to a postremission chemotherapy including four cycles of high-dose cytarabine followed by maintenance courses. In the appropriate arm, GM-CSF was given concurrently with chemotherapy during all cycles of consolidation. CR rates were significantly better in the GM-CSF arm (88 vs 78%, P<0.04), but did not differ after salvage. Patients receiving GM-CSF had a higher 3-year event-free survival (EFS) estimate (42 vs 34%), but GM-CSF did not impact on overall survival. Patients with intermediate-risk cytogenetics benefited more from GM-CSF therapy (P=0.05) in terms of EFS than patients with other cytogenetics. This was also confirmed when considering only patients following the second randomization, or subgroups defined by a prognostic index based on cytogenetics and the number of courses required for achieving CR. Priming of leukemic cells with hematopoietic growth factors is a means of enhancing the efficacy of chemotherapy in younger adults with AML.Leukemia (2007) 21, 453–461. doi:10.1038/sj.leu.2404521; published online 25 January 2007 [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
19. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes.
- Author
-
Kiladjian, J.-J., Bourgeois, E., Lobe, I., Braun, T., Visentin, G., Bourhis, J.-H., Fenaux, P., Chouaib, S., and Caignard, A.
- Subjects
KILLER cells ,MYELODYSPLASTIC syndromes ,APOPTOSIS ,CYTOGENETICS ,BONE marrow diseases ,CYTOKINES - Abstract
Natural Killer (NK) cells are critical in host defense against malignant transformation and are potent antileukemic cytotoxic effectors. In the present study, we investigated the peripheral NK function in patients with myelodysplastic syndromes (MDS). We demonstrated that the peripheral NK cell population was quantitatively normal in MDS patients. Furthermore, NK cells displayed an expression of the activating natural cytotoxicity receptors (NCR) NKp46 and NKp30 as well as NKG2D similar to that observed in donors, but exert a highly decreased constitutive cytolytic activity compared to resting normal NK cells. Although activation with IL-2 resulted in the upregulation of NKp46 expression by MDS-NK cells, their cytolytic function remained deeply altered as compared to activated donor NK cells. In addition, MDS NK cells did not proliferate in vitro, and displayed an increased rate of apoptosis in response to IL-2 stimulation although the spontaneous apoptosis was not significantly increased. Interestingly, a proportion of peripheral MDS-NK cells were derived from the MDS clone as the cytogenetic anomaly found in bone marrow karyotype was also detected in 20–50% of circulating NK cells. In conclusion, NK cells' cytolytic function and proliferative capacities in response to activation by cytokines are profoundly altered in MDS.Leukemia (2006) 20, 463–470. doi:10.1038/sj.leu.2404080; published online 12 January 2006 [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
20. Cooperation of activating Ras/rtk signal transduction pathway mutations and inactivating myeloid differentiation gene mutations in M0 AML: a study of 45 patients.
- Author
-
Roumier, C., Lejeune-Dumoulin, S., Renneville, A., Goethgeluck, A. S., Philippe, N., Fenaux, P., and Preudhomme, C.
- Subjects
ACUTE myeloid leukemia ,GENETIC mutation ,GENE fusion ,GENETIC transduction ,CANCER patients ,BLOOD diseases - Abstract
According to a two hit model of leukaemogenesis, the association between acute myeloid leukaemia (AML)1 mutations and FLT3 gene alterations has been recently described in M0 AML. To further document this model in M0 AML, we screened a cohort of 45 patients to find an association between genes implicated in myeloid differentiation (AML1, Pu1) and genes contributing to cell proliferation: (FLT3, N-RAS, K-RAS, c-KIT, PTPN11). No mutation of the Pu1 gene was observed, whereas mutation in the Runt domain of AML1 gene was observed in 12 of 45 patients (27%). No point mutation or insertion–deletion in the c-kit gene was found. Three point mutations (7%) and 11 internal tandem duplications (22%) were seen in FLT3 gene. Two N-Ras and one PTPN11 mutations were found. No significant correlation between AML1 mutation and FLT3 alteration was found. On the other hand, abnormal cytogenetic findings, especially unfavourable ones, were significantly more frequent in patients without detectable molecular abnormality. These findings suggest at least two different pathogenetic pathways in M0 AML: one associated with AML1 mutation, sometimes in combination with the activating lesion of the tyrosine kinase pathway and generally with normal karyotype, and the other with unfavourable cytogenetic findings.Leukemia (2006) 20, 433–436. doi:10.1038/sj.leu.2404097; published online 19 January 2006 [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
21. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group
- Author
-
Zwierzina, H., Suciu, S., Loeffler-Ragg, J., Neuwirtova, R., Fenaux, P., Beksac, M., Harousseau, J., Nuessler, V., Cermak, J., Solbu, G., Willemze, R., de Witte, T., and Amadori, S.
- Subjects
LEUKEMIA ,MYELODYSPLASTIC syndromes ,BONE marrow ,INTERLEUKIN-3 ,APLASTIC anemia ,CLINICAL trials ,HEMORRHAGE - Abstract
In this randomized phase III study of the EORTC Leukemia Cooperative Group, patients with myelodysplastic syndromes (MDS) with 10–30% bone marrow blasts and hematopoietic failure were treated with low-dose cytosine arabinoside (LD-AraC) (2 × 10 mg/m
2 /day subcutaneously (s.c.) days 1–14) either alone or in combination with rhGM-CSF or interleukin-3 (IL-3) both given s.c. at a dose of 150 μg/day from day 8 to 21. A total of 180 evaluable patients with a median age of 65 years and refractory anemia with an excess of blasts (RAEB, n=107) or RAEB in transformation (RAEBt, n=73) were randomized. There were no differences among the three treatment regimens with respect to numbers of courses applied or treatment delays. Hemorrhage occurred in approximately 40% in all arms, whereas infection rates were higher in the granulocyte/macrophage colony stimulating factor (GM-CSF)- or IL3-containing arm. The overall response rate was 38.6% with no statistically significant difference among the three arms. In summary, a substantial proportion of patients had achieved relatively durable responses in all the three arms. No influence of either growth factor was detected on the grade of cytopenia. Thus, the combination of LD-AraC with GM-CSF or IL-3 cannot be recommended for routine use in a high-risk MDS population.Leukemia (2005) 19, 1929–1933. doi:10.1038/sj.leu.2403934; published online 8 September 2005 [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF
22. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.
- Author
-
Callens, C., Chevret, S., Cayuela, J.-M., Cassinat, B., Raffoux, E., de Botton, S., Thomas, X., Guerci, A., Fegueux, N., Pigneux, A., Stoppa, A.-M., Lamy, T., Rigal-Huguet, F., Vekhoff, A., Meyer-Monard, S., Ferrand, A., Sanz, M., Chomienne, C., Fenaux, P., and Dombret, H.
- Subjects
ACUTE myeloid leukemia ,LEUKEMIA ,LEUCOCYTES ,GENETIC mutation ,BLOOD cell count ,BLOOD diseases - Abstract
Internal tandem duplications (ITDs) of the FLT3 gene have been observed in about 35% of APL cases. If FLT3-ITD is associated with a worse outcome in patients with acute myeloid leukemia (AML) in general, its prognostic value in acute promyelocytic leukemia (APL) is still a matter of debate. We investigated incidence, associated clinical features, and prognostic implication of FLT3-ITD, but also FLT3-D835 point mutation and N-Ras or K-Ras mutations in 119 APL patients, all prospectively enrolled in the two consecutive APL-93 and APL-2000 trials. Mutation incidences were 38, 20, and 4%, for FLT3-ITD, FLT3-D835, and Ras, respectively. The presence of FLT3-ITD was associated with high white blood cell count, high Sanz index, M3-variant subtype, and V/S PML-RARα isoforms. Complete remission (CR), induction death, and death in CR rates were not affected by FLT3 or Ras mutations, as well as cumulative incidence of relapse. However, a trend for a shorter overall survival (P=0.09) was observed in FLT3-ITD patients, because of a very poor postrelapse survival (P=0.02). This feature, which has been also reported in patients with AML in general, is suggestive of an underlying genetic instability in FLT3-ITD patients, leading to the acquisition of additional unknown bad-prognosis gene mutations at relapse.Leukemia (2005) 19, 1153–1160. doi:10.1038/sj.leu.2403790 Published online 12 May 2005 [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
23. CEBPA point mutations in hematological malignancies.
- Author
-
Leroy, H, Roumier, C, Huyghe, P, Biggio, V, Fenaux, P, and Preudhomme, C
- Subjects
TRANSCRIPTION factors ,MYELOID leukemia ,HEMATOPOIESIS ,PROTEINS ,NONLYMPHOID leukemia ,BONE marrow diseases - Abstract
The CCAAT/enhancer-binding protein-alpha (CEBPA) is a transcription factor strongly implicated in myelopoiesis through control of proliferation and differentiation of myeloid progenitors. Recently, several works have reported the presence of CEBPA-acquired mutations in hematological malignancies. In this work, we analyzed characteristics of mutations and their correlation with disease characteristics described in previous studies. In the 1175 patients reported, 146 CEBPA mutations were identified in 96 patients. Mutations were found in the whole gene sequence, but cluster regions were clearly identified. Furthermore, two categories of mutations were reported: out-of-frame ins/del often in the N-terminal region, and in-frame ins/del often in the C-terminal region. CEBPA mutations were reported exclusively in acute myeloid leukemia (AML) (according to WHO classification criteria) and mutated patients preferentially belonged to M1, M2 and M4 FAB subtypes. All but one case belonged to the‘intermediate’prognostic subgroup of MRC classification. In the absence of poor prognostic factors, patients with CEBPA mutation had favorable outcome, very similar to that of the t(8;21), inv(16), t(15;17) subgroup. Systematic analysis of CEBPA mutations, in addition to that of alterations in master genes of hematopoiesis, may be useful to assess the prognosis of AML particularly in patients belonging to the‘intermediate’prognostic subgroup.Leukemia (2005) 19, 329-334. doi:10.1038/sj.leu.2403614Published online 13 January 2005 [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
24. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21).
- Author
-
Leroy, H, de Botton, S, Grardel-Duflos, N, Darre, S, Leleu, X, Roumier, C, Morschhauser, F, Lai, J-L, Bauters, F, Fenaux, P, and Preudhomme, C
- Subjects
CHRONIC myeloid leukemia ,BONE marrow ,THERAPEUTICS ,IMMUNE system ,CELL culture ,IMMUNOLOGY - Abstract
Despite the favorable prognosis of patients with acute myeloid leukemia (AML) with t(8;21)(q22;q22) translocation, relapses still occur in about 30%of the cases but no initial factors can strongly predict the risk of relapse. Several recent studies suggest that monitoring minimal residual disease (MRD) may identify patients at risk of relapse. We prospectively monitored AML1-ETO rearrangement by real-time quantitative PCR (RQ-PCR) in 21 patients uniformly treated in our center. Blood (PB) and bone marrow (BM) samples were collected during and after therapy. At diagnosis, levels of AML1-ETO transcript showed large variations and there was a trend for a higher relapse rate in patients with high pretreatment expression levels (P=0.065). After induction therapy, absolute transcript levels (below 10
-3 , compared to Kasumi cell line), or a greater than 3?log decrease by comparison to diagnosis levels, were significant predictors of the absence of relapse (P=0.02 and P=0.02, respectively). MRD levels after consolidation therapy were also significant indicators of relapse (P=10-5 ). Comparison of BM and PB samples showed similar sensitivity for detecting AML1-ETO transcript. In conclusion, RQ-PCR appears to be an early predictive factor of the relapse risk in AML with t(8;21). PB samples can be used adequately to evaluate the level of MRD by this technique.Leukemia (2005) 19, 367-372. doi:10.1038/sj.leu.2403627 Published online 27 January 2005 [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF
25. Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience.
- Author
-
Lobe, I, Rigal-Huguet, F, Vekhoff, A, Desablens, B, Bordessoule, D, Mounier, C, Ferrant, A, Sanz, M, Fey, M, Chomienne, C, Chevret, S, Degos, L, and Fenaux, P
- Subjects
LEUKEMIA treatment ,GENETICS ,IMMUNOSUPPRESSIVE agents ,THERAPEUTICS - Abstract
With improved treatment of acute promyelocytic leukemia (APL) by all trans retinoic acid (ATRA) combined to anthramyelodysplastic syndrome (MDS) or acute myeloid leukemia (AML, non-APL) occurring cy-cline-aracytin chemotherapy (CT), a larger number of those patients may be at risk of late complications. Recently, the Rome group reported five cases of during the course of 77 APL patients (6.5%) in complete remission (CR). From 1991 to 1998, we treated 677 newly diagnosed cases of APL, and 617 of them achieved CR with ATRA combined to CT (n = 579) or CT alone (n = 38); 246 of them received subsequent maintenance CT with 6 mercapto-purine and methotrexate. With a median follow-up of 51 months, 6 patients (0.97%) developed MDS, 13-74 months after the diagnosis of APL. In all six cases, t(15;17) and PML-RARalpha rearrangement were absent at the time of MDS diagnosis, and karyotype mainly showed complex cytogenetic abnormalities involving chromosomes 5 and/or 7, typical of MDS observed after treatment with alkylating agents, although none of the six patients had received such agents for the treatment of APL. Our findings suggest that MDS can indeed be a long-term complication in APL, although probably at lower incidence than that previously reported. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
26. Prognostic value of GST-p expression in diffuse large B-cell lymphomas.
- Author
-
Ribrag, V, Koscielny, S, Carpiuc, I, Cebotaru, C, Vande Walle, H, Talbot, M, Fenaux, P, and Bosq, J
- Subjects
GLUTATHIONE transferase ,B cell lymphoma ,PROGNOSIS ,DRUG resistance - Abstract
Among mechanisms potentially involved in resistance to alkylating agents and anthracyclines, the glutathione system has been extensively studied in vitro. We analyzed by immunohistochemistry the relation between glutathione s-transferase &pie; (GST-&pie;) expression in tumor cells and outcome in 69 cases of diffuse large B-cell NHL (DLBCL). GST-&pie; expression was considered as low when <50% of tumor cells were stained and high when ⩾50% tumor cells were stained. Median follow-up was 58 months. GST-&pie; expression was correlated with the probability of achieving complete remission (CR). Patients with high GST-&pie; expression had a worse 5-year freedom from progression (FFP). High GST-&pie; expression was associated with a trend for lower survival. In the group of patients with International Prognostic Index (IPI) 0-1, low GST-&pie expression was associated with a CR rate of 88%, a 5-year FFP of 76±20% and a 5-year survival of 78±16% compared to 36, 14±16 and 40±32%, respectively, in patients with a high GST-&pie; expression (P=0.002, P<10[SUP-5] and P=0.01, respectively). No correlation was found between GST-&pie; expression and lactico deshydrogenase serum level, age, Ann Arbor stage, performance status, and IPI index. Both GST-&pie; expression and the IPI index correlated with FFP. After incorporating IPI and GST-&pie; expression in a multivariate analysis for FFP, GST-&pie; expression remained the only prognostic factor (P=0.003). Our findings suggest that GST-&pie; expression had strong prognostic significance in DLBCL, which appears to be independent of other prognostic parameters in those disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
27. Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts.
- Author
-
Ribrag, V, Suzan, F, Ravoet, C, Feremans, W, Guerci, A, Dreyfus, F, Damaj, G, Vantelon, J M, Bourhis, J H, and Fenaux, P
- Subjects
MYELODYSPLASTIC syndromes ,DNA topoisomerase I - Abstract
CPT-11 is an antineoplastic agent which acts as a specific inhibitor of DNA topisomerase 1 and has a broad spectrum of activity in solid tumors. Very few studies have evaluated the activity of CPT-11 in hematological malignancies. We conducted a phase II trial of CPT-11 in 26 patients with high-risk MDS (RAEB 1: n = 4; RAEB 2: n = 9; MDS having progressed to AML: n = 10; CMML: n = 3) who could not receive anthracycline/cytarabine intensive chemotherapy. Induction therapy consisted of four courses of CPT-11 given intravenously at 200 mg/m(2) every 2 weeks. Patient characteristics were: median age, 71 (range 51-77); sex, (M/F), 21/5, median % marrow blasts cells, 13.5 (range 7-52). Cytogenetics according to IPSS were: low-risk n = 13, intermediate-risk n = 6, high-risk n = 3, failure or not done n = 4. Six patients stopped treatment after only one or two courses of CPT-11 due to severe infection (n = 2), progressive disease (n = 3), acute lysis syndrome with renal failure (n = 1). In the 20 patients who received at least three cycles of CPT-11, complete remission was achieved in one case, partial remission in four cases, and hematological improvement in three cases with an overall response rate of 33% in the 26 patients. Duration of response was short (median 4 months, range 1-6 months) and median survival was 8 months (range 1-23 months). Digestive toxicity (diarrhea) occurred in 26/89 (29%) courses, but was mild (grade 1, 20% courses; grade 2 or 3, 9% courses). Hematological toxicity was difficult to assess in non-responders because of initial pancytopenia, but all the patients who responded had grade 3/4 hematological toxicity associated with grade >/=2 infection requiring hospitalization in 18% of the courses. No other major toxicity was observed. Thus CPT-11 has an interesting activity in MDS with excess of blasts; toxicity is easily managed and most patients can be treated in the out-clinic setting. These results suggest that further evaluation of CPT-11 in MDS is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
28. New mechanisms of AML1 gene alteration in hematological malignancies.
- Author
-
Roumier, C, Fenaux, P, Lafage, M, Imbert, M, Eclache, V, and Preudhomme, C
- Subjects
- *
ACUTE myeloid leukemia , *GENETIC mutation , *GENETICS - Abstract
The human AML1 gene (also named CBFA2 or RUNX1), located in the 21q22 chromosomal band, encodes for one of the two subunits forming a heterodimeric transcription factor, the human core binding factor (CBF). AML1 protein contains a highly evolutionary conserved domain of 128 amino acids called runt domain, responsible for both heterodimerization with the β subunit of CBF and for DNA binding. AML1 is normally expressed in all hematopoietic lineages and acts to regulate the expression of various genes specific to hematopoiesis playing a pivotal role in myeloid differentiation. AML1 is one of the genes most frequently deregulated in leukemia through different mechanisms including translocation, mutation and amplification. Translocations lead to the formation of fusion genes encoding for chimerical proteins such as AML1-ETO which induces leukemogenesis. Recently, new mechanisms of AML1 deregulation by point mutations or amplification have been reported. To our knowledge, 51 patients (among 805 studied) with AML1 point mutations have been described. Forty of them have acute myeloid leukemia (AML) most often M0 AML. In this subtype of AML, the frequency of AML1 mutation is significantly higher; 21.5% of patients mutated (34/158). Mutations have also been found with lower frequency in other FAB subtype AML (6 cases), in myeloproliferative disorders (6 cases), in myelodysplastic syndrome (3 cases) and rarely in acute lymphoblastic leukemia (1 case). AML1 gene amplification has been found essentially in childhood ALL (12 cases) and more rarely in myeloid malignancies (4 cases). Here, we reviewed all these cases of AML1 point mutations and amplification and focused on the mechanisms of AML1 deregulation induced by these alterations. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
29. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy.
- Author
-
Boissel, N., Cayuela, J.M., Preudhomme, C., Thomas, X., Grardel, N., Fund, X., Tigaud, I., Raffoux, E., Rousselot, P., Sigaux, F., Degos, L., Castaigne, S., Fenaux, P., and Dombret, H.
- Subjects
ACUTE myeloid leukemia ,DRUG therapy ,GENETICS - Abstract
FLT3 internal tandem duplications (FLT3-ITDs) are present in nearly 25% of patients with AML and have been associated with poor response to conventional therapy and poor outcome. We retrospectively evaluated the effect of reinforced courses of chemotherapy on the prognostic value of FLT3-ITDs in 159 AML patients prospectively enrolled in the ALFA-9000 trial, which randomly compared three reinforced induction regimens (standard 3+7 including high-dose daunorubicin, double induction, and timed-sequential therapy). FLT3-ITD was present in 40/159 (25%) blast samples and associated with high WBC (P = 0.002) and cytogenetics (P < 0.001) with a higher incidence (35%) in patients with a normal karyotype. There was no difference in CR rate between FLT3-wt and FLT3-1TD patients (80% vs 78%). Relapse-free survival (RFS)was similar in both groups (5-year RFS, 33% vs 32%; P = 0.41), even after adjustment for age, sex, WBC, cytogenetics, and treatment arm. A trend to a worse survival was observed in the FLT3-1TD group (estimated 5-year OS, 23% vs 37%; P = 0.09), mainly in patients with a normal karyotype. This was associated with a dramatic outcome in relapsing FLT3-ITD patients (estimated 3-year postrelapse survival, 0% vs 27%; P = 0.04). These results suggest that the bad prognosis associated with FLT3-1TDs in AML might be partly overcome using reinforced chemotherapy. Early detection of FLT3 mutations might thus be useful to intensify induction as well as post-remission therapy in FLT3-ITD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
30. Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia.
- Author
-
Saudemont, A., Buffenoir, G., Denys, A., Desreumaux, P., Jouy, N., Hetuin, D., Bauters, F., Fenaux, P., and Quesnel, B.
- Subjects
GENETIC transformation ,ACUTE leukemia ,IMMUNITY ,GENETICS - Abstract
IL12 is an essential cytokine for the generation of T helper 1 response, natural killer (NK) cells and cytotoxic T lymphocyte (CTL) stimulation. CD154 triggers CD40 on antigen-presenting cells, thus inducing antigen presentation to the immune system and production of IL12. As IL12 and CD154 share several pathways mediating immune response, we investigated in an aggressive murine model of acute leukemia the relative antileukemic efficiency of IL12, CD154 and IL12 + CD154 gene transfer. Live leukemic cells transduced by IL12, CD154, and IL12 + CD154 showed reduced leukemogenicity but CD154 protective effect was reduced when 10[sup 6] leukemic cells were injected. Vaccines with lethally irradiated IL12-transduced cells were able to cure mice previously injected with 104 leukemic cells and adoptive transfer of IL12-induced antileukemic immunity protected recipient mice. NK cytotoxicity was enhanced in mice vaccinated with leukemic cells transduced by IL12, CD154, and CD154 + IL12. IL12 transduced cells induced IFN-γ mRNA in CD4[sup +] and CD8[sup +] T cells isolated from the spleen of vaccinated animals, however, in vivo depletion experiments showed that IL12 vaccine effect was CD4[sup +] but not CD8[sup +] T cell dependent. We conclude that IL12 gene is a more potent candidate than CD154 for gene therapy of acute leukemia. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
31. CORRESPONDENCE.
- Author
-
Grardel, N., Roumier, C., Soenen, V., Lai, J.L., Plantier, I., Gheveart, C., Cosson, A., Fenaux, P., and Preudhomme, C.
- Subjects
ACUTE myeloid leukemia ,MEDICAL genetics ,GENETICS - Abstract
Focuses on the genetic aspects of acute myeloblastic leukemia (AML). Chromosonal rearrangement in the form of inv(16)(p13;q22) or t(16;16)(p13;q22); I type CBFbeta-MYH11 transcript; Treatment recommended for AML.
- Published
- 2002
32. Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx.
- Author
-
Ribrag, V, Hajj, M Ell, Janot, F, Girinsky, T, Domenge, C, Schwaab, G, Fenaux, P, Bosq, J, and Ell Hajj, M
- Subjects
RADIOTHERAPY ,DRUG therapy ,HODGKIN'S disease - Abstract
Nasal NK/T cell is a rare form of usually localized non-Hodgkin's lymphoma (NHL) which generally carries a poor prognosis when treated with conventional NHL chemotherapy protocols. We reviewed 20 consecutive localized stage I/II nasal NK/T cell lymphomas treated at our institution over a 29 year period. Median age was 44 (range 23-71). Front-line therapy was generally radiotherapy alone (35-70 Gy) before 1980 and combination chemotherapy after 1980. Six patients were treated with first-line radiotherapy and they achieved complete remission (CR). Two subsequently received combination chemotherapy. Five of those patients remained in complete remission, after 97+ to 277+ months. Twelve patients were treated with first-line chemotherapy including CHOP or CHOP-like regimen in seven cases, and COP in five cases. Only three of them achieved CR, five had partial response and four had progressive disease. Five of the seven patients treated with CHOP did not achieve complete remission. The nine patients who failed to achieve CR with chemotherapy subsequently received salvage radiotherapy but only two of them obtained CR. Finally, two patients were treated with alternated chemotherapy and radiotherapy and achieved CR, which persisted after 14+ and 26+ months. Median survival was not reached in patients who received front-line radiotherapy, and was 35 months in patients who received front-line chemotherapy. These findings confirm that chemotherapy gives a low complete remission rate in localized nasal NK/T cell lymphoma. By contrast, first-line radiotherapy seems to give favorable results, whereas its results are poorer when administered after resistance to chemotherapy. Whether the use of chemotherapy after radiotherapy, or alternated chemotherapy-radiotherapy regimens give better clinical results than radiotherapy alone will have to be evaluated prospectively in this type of NHL. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
33. Prognostic significance of p16INK4a immunocytochemistry in adult ALL with standard risk karyotype.
- Author
-
Soenen, V, Lepelley, P, Gyan, E, Preudhomme, C, Lai, J-L, Bauters, F, Fenaux, P, and Quesnel, B
- Subjects
LYMPHOBLASTIC leukemia ,IMMUNOCYTOCHEMISTRY ,PROTEIN analysis ,COMPARATIVE studies ,IMMUNOHISTOCHEMISTRY ,KARYOTYPES ,RESEARCH methodology ,MEDICAL cooperation ,ONCOGENES ,PROGNOSIS ,RESEARCH ,SURVIVAL ,FLUORESCENCE in situ hybridization ,EVALUATION research - Abstract
The p16INK4a gene is frequently inactivated in acute lymphoblastic leukemia (ALL), by homozygous deletion. However, p16INK4a protein expression also varies widely in ALL blasts. We investigated the p16INK4a protein expression by immunocytochemistry (ICC) analysis in 76 cases adult ALL. We observed a great variation of the percentage of ICC-positive leukemic cells between samples even in which FISH analysis did not find p16INK4a gene deletion. All patients carrying a p16INK4a gene homozygous deletion were also negative by ICC. ALL with negative p16INK4a ICC were more frequently of T lineage, but no significant differences for white blood cell count, presence of bulky disease, karyotype, hemoglobin level, complete remission rate, overall and event-free survival (EFS) were found. However overall survival and EFS were significantly lower in patients negative by ICC, when analysis was performed in ALL with standard risk karyotype. We also analyzed sequentially at diagnosis and relapse nine cases and observed that one case lost p16INK4a expression between diagnosis and relapse, but that on the contrary three other samples showed increased expression at relapse. These findings suggest that p16INK4a ICC and deletion analysis provide distinct information about ALL cells and that the simple ICC method may be of prognostic value in standard risk adult ALL. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
34. Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases.
- Author
-
Bourgeois, E, Caulier, M T, Rose, C, Dupriez, B, Bauters, F, and Fenaux, P
- Subjects
THROMBOCYTOPENIA ,MYELODYSPLASTIC syndromes ,SPLENECTOMY - Abstract
Thrombocytopenia is generally of central origin in MDS, but can be due to peripheral platelet destruction in some cases. We studied platelet lifespan in 61 MDS cases with platelets < 70,000/mm3 and marrow blasts < 10%. Nine of them (15%) had a major platelet lifespan reduction (< 3.5 days), and were considered for splenectomy. Three of them were not splenectomized due to rapid death, patient refusal and older age plus liver predominance of platelet sequestration, respectively. The remaining six patients (two females and four males, median age 50 years, range 32 to 65) were splenectomized 3 to 21 months after diagnosis. Before splenectomy, five of them had RA and one had CMML. Platelets counts ranged from 5000 to 30,000/mm3 and did not durably respond to other treatments. Three of the patients has a relapse of platelet counts, concomitantly required platelet transfusion due to recurrent blending, whereas three had anemia (two required erythrocyte transfusion) and four had neutropenia. Three months after surgery, platelet counts ranged from 55,000 to 160,000/mm3 (> 100,000/mm3 in four cases), no patient required platelet or erythrocyte transfusion, but there was no effect on neutrophil counts. Three patients had a relapse of platelet counts, concomitant with progression to AML in two of them, whereas the third relapsing case achieved normal platelet counts with further danazol. One patient died with normal platelet counts 12 months after splenectomy (from sepsis, probably related to neutropenia rather than splenectomy). Two patients remained with normal platelet counts 10 and 52 months after surgery. Our findings suggest that the mechanism of thrombocytopenia should be studied more often in 'low risk' MDS (i.e. with low bone marrow blast counts) with thrombocytopenia, as about 15% of them appear to have peripheral platelet destruction. Some of those patients may benefit from splenectomy. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
35. Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes.
- Author
-
Solary, E, Mannone, L, Moreau, D, Caillot, D, Casasnovas, R-O, Guy, H, Grandjean, M, Wolf, J-E, André, F, Fenaux, P, Canal, P, Chauffert, B, Wotawa, A, Bayssas, M, and Genne, P
- Subjects
DRUG resistance ,P-glycoprotein ,CLINICAL trials ,THERAPEUTIC use of alkaloids ,ALKALOIDS ,ANTINEOPLASTIC agents ,COMPARATIVE studies ,DOXORUBICIN ,DRUG resistance in cancer cells ,ELECTROCARDIOGRAPHY ,GLYCOSIDES ,HEART ,LEUCOPENIA ,LYMPHOPROLIFERATIVE disorders ,RESEARCH methodology ,MEDICAL cooperation ,PREDNISONE ,RESEARCH ,DISEASE relapse ,EVALUATION research ,CYCLOPHOSPHAMIDE - Abstract
Overexpression of P-glycoprotein (P-gp) in cancer cells reduces intracellular accumulation of various anticancer drugs including anthracyclines and vinca alkaloids. This multidrug resistance (MDR) phenotype can be reversed in vitro by a number of non-cytotoxic drugs. We have identified the quinine's isomer cinchonine as a potent MDR reversing agent, both in vitro and in animal models. Here, we report an open phase I dose escalation trial in patients with refractory or relapsed malignant lymphoid diseases. Cinchonine dihydrochloride was administered by continuous i.v. infusion for 48 h and escalated over five dose levels ranging from 15 to 35 mg/kg/d. Cinchonine infusion started 24 h before i.v. doxorubicin (25 mg/m2), vinblastine (6 mg/m2), cyclophosphamide (600 mg/m2) and methylprednisolone (1 mg/kg/d) (CHVP regimen) and lasted for 24 h after chemotherapy infusion. Thirty-four patients received 87 cycles of CHVP/cinchonine. The MTD of cinchonine administered by continuous i.v. infusion was 30 mg/kg/d. Prolonged cardiac repolarization was the main dose-limiting toxicity. No ventricular arrhythmia including 'torsade de pointes' was observed. An MDR reversing activity was identified in the serum from every patient and correlated with cinchonine serum level. When infused at 30 mg/kg/d, cinchonine demonstrated a limited influence on doxorubicin pharmacokinetic. We conclude that i.v. infusion of cinchonine might be started 12 h before MDR-related chemotherapy infusion and requires continuous cardiac monitoring but no reduction of cytotoxic drug doses. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
36. Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study.
- Author
-
Hofmann, W K, Kell, W J, Fenaux, P, Castaigne, S, Ganser, A, Chomienne, C, Burnett, R, Kowal, C, Hoelzer, D, and Burnett, A K
- Subjects
TRETINOIN ,CANCER differentiation therapy - Abstract
A multicenter phase II study was initiated to investigate the efficacy, toxicity and tolerability of an oral regimen of 9-cis retinoic acid (9CRA) as a differentiation-inducing agent stimulating both retinoic acid receptor (RAR) and retinoic X receptor (RXR). Thirty patients with myelodysplastic syndromes (MDS) were enrolled into the study. The MDS subtypes were distributed as follows: 14 refractory anaemia (RA), four refractory anaemia with ringed sideroblasts (RARS), and 12 refractory anaemia with excess blasts (RAEB). The age ranged from 40 to 81 years (median 70). None of these had previously received treatment for MDS other than supportive therapy. 9CRA (Alitretinoin capsules, kindly provided by Allergan-Ligand Retinoid Therapeutics) was given daily at 60 mg/m2 p.o. for 1 week, followed by an intra-patient escalation to 100 mg/m2 during the second week, up to a maximum of 140 mg/m2. The planned treatment duration was 48 weeks. Twenty-five were available for assessment. One patient (4%) with RA achieved complete hematological remission. Four (16%), two with RA, two with RAEB, had minor responses resulting in decreased transfusion requirements or increased neutrophils. Thus, the overall response rate was 20% in evaluable patients with MDS and 17% in the study group on an intention-to-treat basis. The most frequent side-effects included headache (77%), dry skin (57%), arthralgias (30%), and rash (23%). In conclusion, although modest responses were noted in this study, the treatment tolerability was suboptimal. It is conceivable that a lower dosage schedule may be efficacious and better tolerated so enabling prolonged exposure which may be required to induce a differentiation effect. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
37. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group.
- Author
-
Fenaux, P., Chevret, S., Guerci, A., Fegueux, N., Dombret, H., Thomas, X., Sanz, M., Link, H., Maloisel, F., Gardin, C., Bordessoule, D., Stoppa, A.-M., Sadoun, A., Muus, P., Wandt, H., Mineur, P., Whittaker, J. A., Fey, M., Daniel, M.-T., and Castaigne, S.
- Subjects
- *
MYELOID leukemia , *TRETINOIN , *ANTINEOPLASTIC agents , *CLINICAL trials , *COMPARATIVE studies , *RESEARCH methodology , *MEDICAL cooperation , *PROGNOSIS , *RESEARCH , *EVALUATION research , *RANDOMIZED controlled trials , *ACUTE promyelocytic leukemia , *LEUKOCYTE count , *THERAPEUTICS - Abstract
First results of a randomized trial (APL91 trial) and other randomized or non-randomized studies have shown that ATRA followed by chemotherapy significantly increased event-free survival (EFS) and survival, and decreased the incidence of relapse by comparison to chemotherapy alone in newly diagnosed APL. We present here long-term follow-up of the APL91 trial. In this trial, 101 patients had been randomized between ATRA followed by three courses of daunorubicin-AraC chemotherapy (ATRA group) and the same chemotherapy alone (chemotherapy group). Results were reanalyzed 73 months after closing of patient entry. Updated results of APL 91 trial found a Kaplan-Meier estimate of EFS and relapse rate at 4 years of 63% and 31% in the ATRA group, as compared to 17% and 78% in the chemotherapy group (P= 10(-4) and relative risk 2.95, P= 10(-4) and relative risk 3.68, respectively). Kaplan-Meier survival at 4 years was 76% in the ATRA group and 49% in the chemotherapy group (P= 0.026, relative risk 2.7). In the chemotherapy group, seven of the 27 relapses occurred after 18 months, but no relapse was seen after 43 months. In the ATRA group, four of the 17 relapses occurred after 18 months, including two late relapses (at 58 and 74 months). In the chemotherapy group, 23 of the 25 patients who relapsed achieved a second CR with ATRA, and the Kaplan-Meier estimate of second relapse was 40% at 30 months. In the ATRA group, the 10 patients who relapsed and were retreated with ATRA achieved a second CR. In conclusion, long-term results of APL91 trial confirm the superiority of the combination of ATRA and chemotherapy over chemotherapy alone in newly diagnosed APL, and that ATRA should be incorporated in the front-line treatment of APL. [ABSTRACT FROM AUTHOR]
- Published
- 2000
38. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR.
- Author
-
Cassinat, B, Zassadowski, F, Balitrand, N, Barbey, C, Rain, J D, Fenaux, P, Degos, L, Vidaud, M, and Chomienne, C
- Subjects
POLYMERASE chain reaction ,LEUKEMIA - Abstract
We took advantage of a recently developed system allowing performance of real-time quantitation of polymerase chain reaction to develop a quantitative method of measurement of PML-RARalpha transcripts which are hallmarks of acute promyelocytic leukemia (APL) with t(15;17) translocation. Indeed, although quantitation of minimal residual disease has proved to be useful in predicting clinical outcome in other leukemias such as chronic myeloid leukemia or acute lymphoblastic leukemia, no quantitative data have been provided in the case of APL. We present here a method for quantitation of the most frequent subtypes of t(15;17) transcripts (namely bcr1 and bcr3). One specific forward primer is used for each subtype in order to keep amplicon length under 200 bp. The expression of PML-RARalpha transcripts is normalized using the housekeeping porphobilinogen deaminase (PBGD) gene. This technique allows detection of 10 copies of PML-RARalpha or PBGD plasmids, and quantitation was efficient up to 100 copies. One t(15;17)-positive NB4 cell could be detected among 106 HL60 cells, although quantitation was efficient up to one cell among 105. Repeatability and reproducibility of the method were satisfying as intra- and inter-assay variation coefficients were not higher than 15%. The efficiency of the method was finally tested in patient samples, showing a decrease of the PML-RARalpha copy number during therapy, and an increase at the time of relapse. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
39. Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients.
- Author
-
Rahmé, R, Thomas, X, Recher, C, Vey, N, Delaunay, J, Deconinck, E, Hirsch, P, Bordessoule, D, Micol, J-B, Stamatoullas, A, Mariette, C, Pautas, C, Bories, P, Marolleau, J-P, Hunault-Berger, M, Fegueux, N, Raffoux, E, Dombret, H, Degos, L, and Fenaux, P
- Subjects
EARLY death ,CAUSES of death ,ACUTE promyelocytic leukemia ,RETINOIC acid receptors ,HOSPITAL admission & discharge - Abstract
The article analyzes the incidence and causes of early death (ED) in acute promyelocytic leukemia (APL) in French centers from December 2006 to December 2011. APL diagnosis is confirmed by the presence of t(15;17) translocation and/or promyelocytic leukemia gene-retinoic acid recepter alpha gene rearrangement. ED is caused by differentiation syndrome, myocardial infarction and multiple organ failure. The rapid admission of patients follows as all-trans retinoic acid is rapidly started.
- Published
- 2014
- Full Text
- View/download PDF
40. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial).
- Author
-
Thomas, X., Fenaux, P., Dombret, H., Delair, S., Dreyfus, F., Tilly, H., Vekhoff, A., Cony-Makhoul, P., Leblond, V., Troussard, X., Cordonnier, C., de Revel, T., Simon, M., Nicolini, F., Stoppa, A. M., Janvier, M., Bordessoule, D., Rousselot, P., Ffrench, M., and Marie, J. P.
- Subjects
- *
ACUTE myeloid leukemia , *GRANULOCYTE-macrophage colony-stimulating factor , *PROGNOSIS , *ANTINEOPLASTIC agents , *CELL division , *CLINICAL trials , *COMPARATIVE studies , *DRUG synergism , *ETOPOSIDE , *HEMATOPOIESIS , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *DISEASE relapse , *EVALUATION research , *MYELOID leukemia , *RANDOMIZED controlled trials , *ACUTE diseases , *CYTARABINE , *MITOXANTRONE - Abstract
The EMA86 study showed efficacy of intensive sequential chemotherapy with mitoxantrone, 12 mg/m2 day on days 1-3, etoposide, 200 mg/m2/day as a continuous infusion on days 8-10 and cytarabine (araC), 500 mg/m2/day as continuous infusion on days 1-3 and 8-10 (EMA regimen) in previously treated patients with AML. The goal of the EMA91 study was to determine whether administration of GM-CSF between the two sequences of EMA chemotherapy and during the second sequence could increase therapeutic efficacy by potentially increasing leukemic cell recruitment into the S phase of cell cycle before the second sequence. One hundred and ninety-two patients aged less than 65 years with previously treated AML received GM-CSF, 5 microg/kg/day or placebo from day 4 to day 8 of EMA chemotherapy. One hundred and twenty were refractory and 72 were in first relapse after a complete remission (CR) of more than 6 months duration. CR rates after one course of chemotherapy were 65% in the GM-CSF group (refractory: 51%; first relapse: 89%), not significantly different from the 59% CR rate (refractory: 46%; first relapse: 81%) in the placebo group. Median time to recovery of neutrophils was 38 and 37 days and median time to last platelet transfusion 32 and 32 days respectively in the GM-CSF and placebo groups. WHO grade > or = 3 non-hematologic toxicities were mainly sepsis (45% and 51%, respectively) and mucositis (34% and 31%) and did not differ between the two groups. Toxic death rate was 5% and 8%, respectively, in the GM-CSF and placebo groups. Patients achieving CR were scheduled to receive six courses of maintenance with reduced-dose EMA. Time to progression tended to be longer in the GM-CSF group (median 154 vs 115 days, progression-free rate at 18 months 33% vs 19%, P = 0.08), particularly in refractory patients (P = 0.06). However, at the current follow-up, this did not translate into a significantly longer disease-free survival and survival. Cell cycle studies showed increased recruitment of cells in the S phase between day 4 and day 8 in the GM-CSF group compared to placebo (P = 0.006). However, this did not significantly relate to prognosis in this cohort of patients. GM-CSF might marginally increase efficacy of sequential chemotherapy without increasing its toxicity in the absence of any detected relationship between this effect and observed leukemic cell recruitment into the cell cycle. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
41. A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients.
- Author
-
Bouabdallah, R, Lefrère, F, Rose, C, Chaïbi, P, Harousseau, J-L, Vernant, J-P, Castaigne, S, Bauduer, F, Zini, J-M, Coso, D, Varet, B, Robert, J, and Fenaux, P
- Subjects
ACUTE myeloid leukemia ,TOXICITY testing - Abstract
We have conducted a phase II outpatient trial testing weekly oral administration of idarubicin (ZAVEDOS-ZVD) alone to determine the rate of objective response and toxicity in poor risk acute myeloid leukemia (AML) patients over 60 years of age. The treatment consisted of three phases: induction, with 20 mg/m2 of ZVD on days 1, 8, 15 and 22; consolidation with 20 mg/m2 of ZVD for 4 weeks; and maintenance with six cycles lasting 3 months and consisting of oral 6 mercapto-purine 2 mg/kg/day, 4 days a week for 2 months; subcutaneous cytarabine 1 mg/kg, once a week for 2 months; and oral ZVD 20 mg/m2 on day 1 and day 8 of the third month. In case of failure after induction course, patients received salvage treatment with 4 weekly oral doses of 40 mg/m2 ZVD. Fifty-one patients with a median age of 76 years were enrolled and could receive induction course. Of these 51 patients, 37 could receive subsequent courses, which consisted either of consolidation, or salvage. Only 11 patients underwent maintenance treatment. Sixty-three percent of patients had to be hospitalized during induction, for a median duration of 14.5 days, and 87% required hospitalization during salvage for a median duration of 17.5 days. Only five patients (38%) required hospitalization during consolidation. There were three toxic deaths (6%), two from hemorrhage and one from pulmonary embolism. The overall response rate was 29%, with 12 patients in complete response (25%) and two in partial response (4%). The median overall survival rate is 4 months for the whole population, and the median DFS is 9.6 months among the 14 responding patients. The results of this trial show that this new weekly schedule of oral ZVD chemotherapy is feasible and effective in poor risk elderly patients with AML. This regimen may be helpful for patients unable to tolerate intensive intravenous regimens, and is a real alternative to palliative treatments. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
42. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay.
- Author
-
Preudhomme, C, Révillion, F, Merlat, A, Hornez, L, Roumier, C, Duflos-Grardel, N, Jouet, J P, Cosson, A, Peyrat, J P, and Fenaux, P
- Subjects
MYELOID leukemia ,BONE marrow transplantation - Abstract
Quantitative competitive RT-PCR techniques have been developed to detect BCR-ABL fusion transcripts in CML but they are hardly reproducible. In this work, we have developed BCR-ABL quantification by real time RT-PCR using the ABI PRISM 7700 (Perkin Elmer), a new technique which allows simple and rapid quantification of a target sequence during the extension phase of PCR amplifications. A fluorogenic probe labeled with both a reporter dye at the 5' end and a quencher-dye at the 3' end hybridizes to the target sequence on the third exon of the ABL gene. The exonuclease activity of the Taq DNA polymerase cleaves the probe and releases the reporter dye, resulting in an increase in the fluorescence signal. The absolute copy number of the target sequence (BCR-ABL) or a control gene (ABL) in an unknown sample can then be calculated using a calibration curve prepared from a set of BCR-ABL RNA standards, and results are expressed as a BCR-ABL/ABL ratio. In our hands, the sensitivity of a serial dilution of total RNA from a positive cell line (K562) in a negative cell line (HL60) was 10(-4). Fifteen CML patients in cytogenetic CR, including 11 allografted patients, two autografted patients and two patients treated by IFN were studied sequentially by this new real time quantitative RT-PCR technique in parallel with conventional qualitative two round nested RT-PCR. The two autografted patients showed high BCR-ABL/ABL ratio in all samples. The two patients treated by IFN showed a progressive decrease in the ratio. In the 11 allografted patients, four were sequentially studied 2 years or more after allo-BMT, and all ratios were below 10(-4). The four patients remained in clinical and cytogenetic CR. The seven other allografted patients were studied immediately after the procedure. Three of them showed a progressive decrease in the BCR-ABL/ABL ratio which reached 10(-4) 7 months after allo-BMT. The three patients remained in hematologic and cytogenetic CR. The remaining four allografted patients had progressive increase of BCR-ABL ratio; three developed cytogenetic relapse 9, 11, 28 months after allo-BMT, and the last patient remained in cytogenetic CR in the bone marrow but developed granulocytic sarcoma. Results of real-time quantitative RT-PCR were in agreement with those of qualitative two round nested PCR. However, evolution changes in the results of real-time quantitative RT-PCR often preceded those of the conventional technique: a decrease of the BCR-ABL/ABL ratio preceded progression from first round to second round positivity and then negativity with the classical technique; conversely, an increase in the ratio preceded evolution with the classical technique. Thus, real-time quantitative RT-PCR may show better correlation with clinical and cytogenetic evolution than conventional qualitative techniques and may help in making early therapeutic decisions in CML, especially after molecular relapse. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
43. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using an in situ RT-PCR assay.
- Author
-
Preudhomme, C, Chams-Eddine, L, Roumier, C, Duflos-Grardel, N, Denis, C, Cosson, A, and Fenaux, P
- Subjects
MYELOID leukemia ,POLYMERASE chain reaction ,IN situ hybridization ,RNA analysis ,BONE marrow transplantation ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,PROTEINS ,RESEARCH ,EVALUATION research ,CHRONIC myeloid leukemia ,REVERSE transcriptase polymerase chain reaction - Abstract
Methods of minimal residual disease (MRD) detection in chronic myelogenous leukemia (CML) include chromosome analysis, reverse transcriptase polymerase chain reaction (RT-PCR) and fluorescence in situ hybridization (FISH) techniques. We report a novel method to detect intracellular BCR-ABL messenger on single cells using in situ RT-PCR, which can be performed on blood and marrow slides, without extraction of the nucleic acid. After cellular permeabilization and fixation, the mRNA BCR-ABL was reverse transcribed and amplified by PCR using digoxigenin-labelled dUTP. The reaction was revealed with the anti-digoxigenin FITC antibody. On the fluorescent microscope, a strong positive green fluorescence signal was observed in 98-99% cells in Ph1-positive cell lines. A faint signal was detected in 1.5% and 2% of negative cell lines. Likewise, a faint signal was found in 1.6-2.8% of the cells in five normal controls (mean 2.2 +/- 1.1%). The positive threshold for in situ RT-PCR was therefore determined as mean + 2 s.d. = 4.4% cells. We used in situ RT-PCR by comparison to cytogenetics (at least 30 mitoses examined), and two-step RT-PCR (10(-6) sensitivity in our hands) in bone marrow samples from 13 CML patients: two patients at diagnosis and 11 patients in hematological remission after alpha interferon (three patients), hydroxyurea (one patient) autologous bone marrow transplantation (BMT) (one patient) and allogeneic BMT (six patients). In the two diagnostic patients, 90 and 95% cells were respectively strongly positive by in situ RT-PCR. In the six patients treated by allogeneic BMT, the median percentage of positive cells was 2.4% (range 1.8-3.2). All six patients had normal karyotype and negative two-step RT-PCR results. In the five other patients, two were treated by hydroxyurea alone or autologous BMT, and 11 and 13% of the cells were strongly positive; three were treated with interferon and 14-62% of the cells were positive, generally weakly. All five patients had persistence of Ph1 (in 9-56% mitoses), and positive RT-PCR results after one round. In conclusion, in situ RT-PCR can specifically identify cells with BCR-ABL transcript and its results are concordant with those of karyotype and RT-PCR. Because of its limited sensitivity and specificity, however, it appears to have limited value in the analysis of MRD. On the other hand, it can evaluate the presence and intensity of BCR-ABL fusion transcript at the single cell level, and this could be useful in treatment monitoring. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
44. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdes.
- Author
-
Wattel, E, Solary, E, Leleu, X, Dreyfus, F, Brion, A, Jouet, J P, Hoang-Ngoc, L, Maloisel, F, Guerci, A, Rochant, H, Gratecos, N, Casassus, P, Janvier, M, Brice, P, Lepelley, P, Fenaux, P, Français des Myélodysplasies, Groupe, and Ouest-Est d’étude des Leucémies aiguës myéloïdes, Groupe
- Subjects
STEM cells ,CELL transplantation ,LEUKEMIA - Abstract
We prospectively assessed autologous stem cell transplantation for consolidation treatment in a trial of intensive chemotherapy in high risk myelodysplastic syndromes (MDS). In this trial, patients aged 55 years or less with no HLA-identical sibling and achieving CR were scheduled to receive unmanipulated autologous bone marrow transplantation (ABMT) preceded by a consolidation chemotherapy course. Forty-two of the 83 patients aged 55 years or less included in the trial (51%) achieved CR. Three were allografted in CR. Twenty-four of the remaining 39 patients who achieved CR (62%) received ABMT (16 patients) or autologous peripheral blood stem cell transplantation (APSCT) (eight patients). Indeed, as bone marrow harvest was often insufficient, APSCT was subsequently proposed after mobilization by consolidation chemotherapy followed by G-CSF. The conditioning regimen combined cyclophosphamide and busulfan. ABMT and APSCT were performed 1-7 months (median 3) after CR achievement. Hematological reconstitution occurred in all patients and tended to be faster after APSCT than ABMT although not significantly. Three patients died from the procedure, nine relapsed after 2-26 months and 12 (50%) were still in CR after 8-55 months. In autografted patients, median Kaplan-Meier disease-free survival and survival were 29 and 33 months from the autograft, respectively. Thus, ABMT or APSCT can be performed in almost two-thirds of MDS patients who achieve CR with intensive chemotherapy. PBSC collection may yield higher numbers of stem cells than marrow collection in some cases, and could improve the percentage of MDS patients autografted in CR. Longer follow-up is required to determine if autograft will prolong CR duration in at least some patients. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
45. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases.
- Author
-
Merlat, A, Lai, J L, Sterkers, Y, Demory, J L, Bauters, F, Preudhomme, C, and Fenaux, P
- Subjects
ACUTE myeloid leukemia ,MYELODYSPLASTIC syndromes ,ANTINEOPLASTIC agents ,CHROMOSOMES ,CLINICAL trials ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,GENETIC mutation ,RADIATION carcinogenesis ,RESEARCH ,EVALUATION research ,MYELOID leukemia ,RANDOMIZED controlled trials ,ACUTE diseases - Abstract
Two main types of therapy-related acute myeloid leukemias (tAML) and myelodysplastic syndromes (tMDS) have been described. The first classical type typically occurs late after use of alkylating agents and presents as MDS with -7/del 7q and/or -5/del5q. The second form occurs early after the use of agents targeted at topoisomerase II, and presents as AML with 11q23 or other rearrangements of de novo AML. Recently, we and others reported, in AML and MDS, a strong correlation between cytogenetic rearrangements leading to 17p deletion, a specific type of dysgranulopoiesis and p53 mutation; several of those cases of 17p- syndrome were therapy-related. Over the last 15 years, we observed 25 cases of tAML and tMDS with 17p deletion, which represented 36% of the AML and MDS with 17p deletion diagnosed during that period. Median age was 59 years. Twenty-one patients had tMDS and four tAML. Typical dysgranulopoiesis and p53 mutation and/or overexpression were seen in 22 of 24 and 16 of 19 evaluable patients, respectively. 17p deletion resulted from unbalanced translocations involving 17p (18 cases), monosomy 17 (five cases), i(17q) (one case) or del 17p (one case). Twenty-one patients also had -5/del 5q, and/or -7/del 7q. Median interval from treatment of the first tumor of tAML and tMDS was 94 months (range 19-252). Median survival was only 7 months. Based on primary tumor and antineoplastic agents used, patients could be relatively well divided into two groups: a first group of 11 cases, occurring mainly after a lymphoid neoplasm (eight cases) treated by chemotherapy with an alkylating agent (10 cases), and a second group of 14 cases occurring after essential thrombocythemia (ET) or polycythemia vera (PV) treated mainly by hydroxyurea (10 cases), pipobroman (eight cases), 32P (six cases) but rarely by alkylating agents (two cases). -7/del 7q was found in 10 of the 11 patients in the first group, as compared to three of the 14 patients of the second group (P = 0.0001). Therefore, therapy-related cases represent a high proportion of AML and MDS with the 17p- syndrome. They have many features in common with classical tMDS and tAML, including long interval from the first tumor, a usual preleukemic phase, and frequent occurrence of -5/del 5q. About one half of them, in addition, occur after alkylating agents and generally carry -7/del 7q. The other half, however, occur mainly after ET or PV treated by hydroxyurea or other non-alkylating agents, and usually have no -7/del 7q. These findings bring further support to a possible relationship between prior drugs used and cytogenetic rearrangements in tAML and tMDS. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
46. The VIM3-AraC regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hodgkin's lymphoma. A prospective study of 71 consecutive cases.
- Author
-
Plantier-Colcher, I, Dupriez, B, Simon, M, Detourmignies, L, Jouet, J P, Fenaux, P, Bauters, F, and Morel, P
- Subjects
LYMPHOMAS ,STEM cells ,DRUG therapy ,ANTINEOPLASTIC agents ,LYMPHOMA treatment ,AUTOGRAFTS ,CLINICAL trials ,COMBINED modality therapy ,COMPARATIVE studies ,HEMATOPOIETIC stem cell transplantation ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,METHOTREXATE ,PROGNOSIS ,PROTEINS ,RESEARCH ,DISEASE relapse ,EVALUATION research ,RANDOMIZED controlled trials ,CYTARABINE ,MITOXANTRONE ,METHYLPREDNISOLONE ,PREDNISOLONE ,IFOSFAMIDE - Abstract
We evaluated with an intent-to-treat analysis the response rate, the disease-free survival (DFS), and the overall survival after a multidrug salvage regimen (VIM3ARAC), followed by stem-cell transplantation (SCT) in case of response, in patients with aggressive non-Hodgkin's lymphoma (NHL) who progressed on or after the first-line therapy. Seventy-one patients (refractory: 15; relapse 'on therapy': 36; and relapse 'off therapy': 20) received two courses of VIM3ARAC (teniposide, ifosfamide, mitoxantrone, mitoguazone, high-dose methotrexate, high-dose cytarabine, prednisolone). SCT was performed only in patients with minimal disease after the second course. The response rate was 72%. It was not influenced by response to first-line therapy. Forty-eight patients (68%), including 32 complete responders, fulfilled response criteria for SCT. Thirty-six patients underwent SCT (allogeneic: 3; autologous: 33). The 4-year DFS rate of the 48 responding patients was 39%. The actuarial survival at 4 years was 34% for all patients. Relapse off therapy and a performance status <2 at relapse were the only two independent favorable prognostic factors for survival. In conclusion, VIM3AraC is associated with a high response rate in relapsing and refractory aggressive NHL. Up to half of the patients could receive SCT. This chemotherapy, followed by SCT could durably salvage 34% of these patients. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
47. Myelodysplasia during the course of myeloma. Restriction of 17p deletion and p53 overexpression to myeloid cells.
- Author
-
Soenen, V, Preudhomme, C, Roumier, C, Laï, J L, Lepelley, P, Facon, T, Pagniez, D, and Fenaux, P
- Subjects
MULTIPLE myeloma ,MYELODYSPLASTIC syndromes ,CHROMOSOME abnormalities ,CHROMOSOMES ,COMPARATIVE studies ,GENETIC polymorphisms ,IMMUNOPHENOTYPING ,RESEARCH methodology ,MEDICAL cooperation ,GENETIC mutation ,ONCOGENES ,PROTEINS ,RESEARCH ,FLUORESCENCE in situ hybridization ,EVALUATION research ,DISEASE complications - Abstract
We report a case of myelodysplastic syndrome (MDS) occurring during the course of multiple myeloma (MM) treated by alkylating agents. Karyotype showed unbalanced t(5;17), resulting in 17p deletion. Dysgranulopoïesis typical of the '17p-syndrome' and p53 mutation and overexpression were present. A combination of FISH and immunophenotype analysis (FICTION, analysis) showed that 17p deletion was restricted to myeloid cells, and that p53 overexpression was also restricted to myeloid cells. These findings strongly argue against a common clonal origin of MM and MDS, and support the hypothesis that MM and MDS were clonally unrelated, and that MDS was indeed secondary to treatment with alkylating agents. [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
48. Association between myelodysplastic syndromes and inflammatory bowel diseases. Report of seven new cases and review of the literature.
- Author
-
Hebbar, M, Kozlowski, D, Wattel, E, Mastrini, S, Diévart, M, Duclos, B, Bonaz, B, d’Almagne, H, Belaiche, J, Colombel, J-F, Fenaux, P, and d'Almagne, H
- Subjects
MYELODYSPLASTIC syndromes ,CROHN'S disease ,COLON diseases ,INFLAMMATORY bowel diseases ,DISEASE complications - Abstract
We report seven patients with both myelodysplastic syndrome (MDS) and inflammatory bowel disease (IBD): Crohn's disease in six cases, ulcerative colitis in one case. We describe their characteristics, and those of 10 previously published similar cases are presented here. Median age at diagnosis of IBD (61 years) was high, as compared to the usual age at diagnosis of IBD. IBD was diagnosed first in nine cases, MDS first in one patient, and both diseases were diagnosed simultaneously in seven cases. Concerning IBD, there was a strong predominance of Crohn's disease (15/17 cases), with an unusually high frequency of colonic involvement (11/15 cases). MDS, in 12/17 cases, showed no excess of marrow blasts. Cytogenetic analysis was abnormal in five of the 13 evaluable cases. These observations suggest that the association between MDS and IBD may not be fortuitous in some cases, and that, in particular, patients with IBD and anemia of nonobvious origin should be evaluated for MDS. The pathogenesis of those associations, however, remains unclear. [ABSTRACT FROM AUTHOR]
- Published
- 1997
- Full Text
- View/download PDF
49. Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL).
- Author
-
Preudhomme, C, Henic, N, Cazin, B, Laï, J L, Bertheas, M F, Vanrumbeke, M, Lemoine, F, Jouet, J P, Deconninck, E, Nelken, B, Cosson, A, Fenaux, P, and Lai, J L
- Subjects
LYMPHOBLASTIC leukemia ,CHROMOSOMES - Abstract
We sequentially performed cytogenetic analysis and RT-PCR analysis of BCR-ABL transcripts in 17 cases of Ph1-positive ALL who had achieved hematological complete remission (CR) with intensive chemotherapy (CT). Sixteen cases were studied prospectively. All but one of the patients had reached cytogenetic CR, but cytogenetic has low sensitivity in predicting relapse. Twelve patients relapsed, three died in first CR and two were alive in first CR. Two of five, two of four, and five of nine patients who were allografted (in first or second CR), autografted and received consolidation CT, respectively, achieved negative two-round PCR in the bone marrow (BM): three died in CR, three remained in CR with negative two-step PCR in the BM and three relapsed after 22 to 28 months. In all cases, relapse was preceded by switch to PCR positivity in the BM by 4 to 6 months. The remaining nine patients remained PCR-positive in the BM and relapsed after 2 to 16 months. In the four autografted cases, PCR was positive at the time of bone marrow harvest. The two patients who received a purged transplant achieved negative PCR and prolonged CR, whereas the two patients who received an unpurged transplant remained PCR positive and relapsed. In 34% of the samples where analysis was concomitant, sensitivity of PCR proved lower in the blood than in the BM. These findings show that RT-PCR is a useful tool in the monitoring of MRD in Ph1 positive ALL. [ABSTRACT FROM AUTHOR]
- Published
- 1997
- Full Text
- View/download PDF
50. Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine.
- Author
-
Itzykson, R., Thépot, S., Eclache, V., Quesnel, B., Dreyfus, F., Beyne-Rauzy, O., Turlure, P., Vey, N., Recher, C., Boehrer, S., Gardin, C., Adès, L., and Fenaux, P.
- Subjects
LETTERS to the editor ,MYELODYSPLASTIC syndromes ,KARYOTYPES - Abstract
A letter to the editor is presented in response to the article "Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype," by M. M. Patnaik and colleagues in the 2011 issue.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.